Locoregional Treatment of Glioblastoma With Targeted α Therapy

医学 多塔 总体生存率 内科学 胶质母细胞瘤 不利影响 肿瘤科 核医学 癌症研究 体内 生物 生物技术
作者
Leszek Królicki,Jolanta Kunikowska,Frank Bruchertseifer,Radosław Kuliński,Dariusz Pawlak,Henryk Koziara,Rafał Rola,Alfred Morgenstern,Adrian Merlo
出处
期刊:Clinical Nuclear Medicine [Lippincott Williams & Wilkins]
卷期号:48 (5): 387-392 被引量:10
标识
DOI:10.1097/rlu.0000000000004608
摘要

Glioblastoma (GB) is the most malignant primary brain tumor. Therefore, introduction of new treatment options is critically important. The aim of this study was to assess local treatment with α emitters [ 213 Bi]Bi-DOTA-substance P (SP) and [ 225 Ac]Ac-DOTA-SP.Treatment was performed as salvage therapy in patients with recurrent primary and secondary GB. [ 213 Bi]Bi-DOTA-SP with injected activity 1.85 GBq per cycle was used in 20 primary (48.2 ± 11.8 years old) and in 9 secondary (38.8 ± 10.8 years old) GB patients and [ 225 Ac]Ac-DOTA-SP in 15 primary (45.1 ± 9.9 years old) and in 6 secondary (37.8 ± 6.4 years old) GB patients with a dose escalation scheme (10, 20, and 30 MBq).Local treatment with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP was well tolerated with only few adverse effects. There was no statistically significant difference between [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP groups in survival parameters. For primary GB, survival parameters of patients treated with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP were as follows(in months): progression-free survival time, 2.7 versus 2.4; OS-d (overall survival from time of diagnosis to death from any cause), 23.6 versus 21.0; OS-t (overall survival from the start of treatment to death from any cause), 7.5 versus 5.0; and OS-r (overall survival from recurrence in primary tumors to death from any cause), 10.9 versus 12.0. Survival parameters of secondary GB patients treated with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP were as follows (in months): progression-free survival time, 5.8 versus 2.4; OS-d, 52.3 versus 65.0; OS-t, 16.4 versus 16.0; and OS-c (overall survival from conversion into secondary GB multiforme to death from any cause), 18.4 versus 36.0.The similarity results of 213 Bi or 225 Ac may suggest that the local treatment of brain tumors can be greatly simplified. The experience to date shows that local radioisotope treatment of brain tumors requires further dosimetry studies, taking into account the complexity of biological processes.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
东方元语应助Solkatt采纳,获得20
刚刚
gp完成签到,获得积分20
2秒前
下下的交完成签到,获得积分10
2秒前
章鱼完成签到,获得积分10
2秒前
科研通AI6.4应助L563采纳,获得10
2秒前
奋斗的世立完成签到,获得积分10
3秒前
九秋霜完成签到,获得积分10
3秒前
东方元语应助zijunzhou采纳,获得20
4秒前
小万发布了新的文献求助10
4秒前
小蘑菇应助PMP采纳,获得10
5秒前
5秒前
冯冯完成签到,获得积分10
6秒前
6秒前
Hello应助刘艺珍采纳,获得10
6秒前
积极无敌完成签到 ,获得积分10
7秒前
吕哥完成签到 ,获得积分10
9秒前
10秒前
FashionBoy应助冯冯采纳,获得10
10秒前
11秒前
11秒前
CodeCraft应助科研通管家采纳,获得10
11秒前
FashionBoy应助科研通管家采纳,获得10
12秒前
12秒前
12秒前
12秒前
12秒前
赘婿应助科研通管家采纳,获得10
12秒前
12秒前
12秒前
12秒前
隐形曼青应助科研通管家采纳,获得10
12秒前
思源应助科研通管家采纳,获得10
13秒前
小蘑菇应助科研通管家采纳,获得10
13秒前
Hui完成签到,获得积分10
13秒前
13秒前
小万完成签到 ,获得积分10
13秒前
cyyan发布了新的文献求助10
13秒前
14秒前
15秒前
丰富语蕊应助钱江铫采纳,获得10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
化工安全与环保 1000
Autoparametric Resonance in Mechanical Systems 1000
基于锂离子电池正极材料回收的绿色溶剂开发及工程化应用研究 800
Cosmos as Art Object: Studies in Plato's Timaeus and Other Dialogues 600
Management and the Arts 510
Matrix Methods in Data Mining and Pattern Recognition Second Edition 510
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7652665
求助须知:如何正确求助?哪些是违规求助? 9224020
关于积分的说明 19811416
捐赠科研通 7218607
什么是DOI,文献DOI怎么找? 3279007
关于科研通互助平台的介绍 2439738
邀请新用户注册赠送积分活动 2278186